CSV September 8, 2023 through September 8, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DROSPIRENO	IM	*USP37–NF32*	2739	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First*	Line 2 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NE AND ETHINYL ESTRADIOL TABLETS	PUR ITIES/*Organic Impuri ties/ Chromatographi c system*						*Supplement to USP38–NF33*	*Detector 2*: Change Monitor the signal at 344 nm between 37 and 42 min. to: Monitor the signal at 344 nm for ethinyl estradiol related compound B (typically between 37 and 42 min).
PSEUDOEPHE DRINE HYDRO CHLORIDE	ASSAY/ *Procedure*	*USP37–NF32*	4481	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 2 of *System suitability solution*: Change 0.02 mg/mL of USP Ephedrine Sulfate RS to: 0.002 mg/mL of USP Ephedrine Sulfate RS
STERILE WATER FOR INJECTION	CHEMICAL INFORMATION	*USP37–NF32*	5175	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Add the chemical formula and molecular

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								weight: H_2O 18.02
STERILE PURIFIED WATER	ADDITIONAL REQUIREMENTS	*USP37–NF32*	5176	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Add a section: *USP Reference Standards <11>* USP 1,4-Benzoquinone RS USP Sucrose RS
DEXCHLORPHENIRAMINE MALEATE	IMPURITIES/*Organic Impurities*	*First Supplement to USP37–NF32*	6626	26-Sep-2014	1-Oct-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Standard solution*: 2.2 ?g/mL of USP Dexchlorpheniramine Maleate RS in *Diluent*, to: 2.8 ?g/mL of USP Dexchlorpheniramine Maleate RS in *Diluent*,
AMIFOSTINE	ASSAY/*Procedure*/*System suitability*/*Suitability requirements*	*USP37–NF32*	1717	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Column efficiency*: Change NLT 100 to: NLT 1000
TIZANIDINE	ASSAY/	*Second*	Online	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	*Procedure/System suitability*	*Supplement to USP37–NF32*					*Supplement to USP38–NF33*	*Sample*: *Standard solution* to: *Samples*: *System suitability solution* and *Standard solution* AND Change *Resolution*: NLT 4.0 between tizanidine and tizanidine related compound C; NLT 4.0 between tizanidine and tizanidine related compound B *Tailing factor*: NMT 2.0 *Relative standard deviation*: NMT 2.0% to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Resolution: NLT 4.0 between tizanidine and tizanidine related compound C; NLT 4.0 between tizanidine and tizanidine related compound B, *System suitability solution* *Tailing factor*: NMT 2.0, *Standard solution* *Relative standard deviation*: NMT 2.0%, *Standard solution*
CEFUROXIME FOR INJECTION	*Constituted solution*	*USP37–NF32*	2246	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 3: Change meets the requirements for *Constituted Solutions* under *Labeling* under *Injections <1>*.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: meets the requirements for *Constituted Solutions* under *Injections <1>*.
DULOXETINE DELAYED-RELEASE CAPSULES	IDENTIFICATION	*USP37–NF32*	2743	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Change *A. Infrared Absorption <197S>* to: *A. Infrared Absorption <197F>*
LEVODOPA	IMPURITIES	*USP37–NF32*	3533	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Row 6 of Column 1 of *Table 1*: Change 1-Veratrylglycine to: L-Veratrylglycine[a] AND Add a footnote: [a] 3-(3,4-Dimethoxyphenyl)-L-alanine.
VINBLASTINE SULFATE	IDENTIFICATION/*B.*	*USP37–NF32*	5150	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to*	Line 1 of *Sample*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							USP38–NF33	Change 100 mg/mL in water to: 10 mg/mL in water
CEFADROXIL	ASSAY/ *Procedure*	*First Supplement to USP37–NF32*	6602	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 3 of *Sample solution*: Change USP Cefadroxil RS to: Cefadroxil
METHODS FOR THE DETERMINATION OF PARTICULATE MATTER IN INJECTIONS AND OPHTHALMIC SOLUTIONS	LIGHT OBSCURATION PARTICLE COUNT TEST/ *Instrument Standardization Tests*/*Particle Counting Accuracy—System Suitability*	*USP37–NF32*	1301	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 26 of *Method 1—MWHC Instruments*: Change P_B is the average particle count obtained from the suspension; to: P_S is the average particle count obtained from the suspension;
TERBINAFINE	ADDITIONAL R	*First*	6704	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First*	Line 2 of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLORIDE	EQUIREMENTS/*USP Reference Standards <11>*	*Supplement to USP37–NF32*					*Supplement to USP38–NF33*	Terbinafine Related Compound A RS: Change *N* -Methyl-*C* -(naphthalen-1-yl)methanamine . to: *N* -Methyl-*C* -(naphthalen-1-yl)methanamine hydrochloride. AND Line 2 of USP Terbinafine Related Compound B RS: Change (2*Z*)-*N* , 6, 6-Trimethyl-*N* -(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(2*Z*)-*N* , 6, 6-Tr imethyl-*N* -(naphthalen-1- ylmethyl)hept-2- en-4-yn-1-amin e hydrochloride. AND Line 2 of USP Terbinafine Related Compound C: Change (2*E*)-*N* , 6, 6-Tr imethyl-*N* -(naphthalen-2- ylmethyl)hept-2- en-4-yn-1-amin e. to: (2*E*)-*N* , 6, 6-Tr imethyl-*N* -(naphthalen-2-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ylmethyl)hept-2-en-4-yn-1-amine hydrochloride. AND Line 2 of Terbinafine Related Compound D RS: Change (2*E*)-*N* , 6, 6-Trimethyl-*N* -[(4-methylnaphthalen-1-yl)methyl]hept-2-en-4-yn-1-amine. to: (2*E*)-*N* , 6, 6-Trimethyl-*N* -[(4-methylnaphthalen-1-yl)methyl]hept-2-en-4-yn-1-amine hydrochloride.
CEFTIZOXIME FOR	*Constituted solution*	*USP37–NF32*	2240	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to*	Line 1: Change At the time of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
INJECTION							*USP38–NF33*	use, it meets the requirements for *Constituted Solutions* under *Labeling* under *Injections <1>*. to: At the time of use, it meets the requirements for *Constituted Solutions* under *Injections <1>*.
DOXAPRAM HYDROCHLORIDE INJECTION	ASSAY/ *Procedure*	*USP37–NF32*	2708	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 7 of *Analysis*: Change R_U = peak response ratio of the doxapram to the internal standard from the *Sample solution* R_S = peak response ratio of the doxapram to the internal standard from the *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution to: R_U = peak response ratio of doxapram to the internal standard from the *Sample solution* R_S = peak response ratio of doxapram to the internal standard from the *Standard solution*
LEFLUNOMIDE	IMPURITIES/*Organic Impurities*/*Procedure 2*	*USP37–NF32*	3502	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 3 of *Analysis*: Change [Note—Disregard any peak with an area less than the leflunomide peak from the *System suitability solution*. to: [Note—Disregard any peak with

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								an area less than the leflunomide peak from the *Sensitivity solution*.
NALTREXONE HYDROCHLORIDE	*Assay*	*USP37–NF32*	3922	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 7 of *Procedure*: Change (377.86/341.41) $10C(r_U/r_S)$ in which 377.86 and 341.41 are the molecular weights of naltrexone hydrochloride and naltrexone to: (377.86/341.40)$10C(r_U/r_S)$ in which 377.86 and 341.40 are the molecular weights of naltrexone hydrochloride and naltrexone
VITAMIN E ASSAY	ASSAY/ *Procedure 4*/	*First Supplement to USP37–NF32*	6338	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Flow rate*: Change 1.5 mL/min

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Chromatographic system							to: 1 mL/min
GENERAL NOTICES TO USP-NF	6. TESTING PRACTICES AND PROCEDURES/*6.50. Preparation of Solutions*	*First Supplement to USP37–NF32*	6291	25-Jul-2014	1-Aug-2014	*USP38–NF33*	*USP38–NF33*	Line 6 of *6.50.20. Solutions*: Change An expression such as “(1 in 10)” means that 1 part *by volume* of a liquid shall be diluted with a sufficient quantity of the diluent or solvent to make the volume of the finished solution 10 parts *by volume*. An expression such as “(20:5:2)” means that the respective numbers of parts, by volume, of the designated liquids shall be

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mixed, unless otherwise indicated. to: An expression such as “(1 in 10)” means that 1 part *by volume* of a liquid shall be diluted with, or 1 part *by weight* of a solid shall be dissolved in, a sufficient quantity of the diluent or solvent to make the volume of the finished solution 10 parts *by volume*. An expression such as “(20:5:2)” means that the respective numbers of parts, by volume, of the designated

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								liquids shall be mixed, unless otherwise indicated.
SUFENTANIL CITRATE	ASSAY/*Procedure/System suitability/Suitability requirements*	*First Supplement to USP37–NF32*	6701	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Relative standard deviation*: Change NMT 0.7% to: NMT 0.73%
BUMETANIDE	IMPURITIES	*USP37–NF32*	2024	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Row 4 of Column 1 of *Table 1*: Change Paroxetine butyl 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoate to: Butyl 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoate
ROPINIROLE HYDROCHLORIDE	IMPURITIES/*Organic Impurities, Procedure 1/System suitab*	*Revision Bulletin (Official May 01, 2014)*	Online	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Tailing factor*: Change NLT 2.0 for the ropinirole peak to: NMT 2.0 for the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	ility/Suitability requirements							ropinirole peak
CHLORDIAZEPOXIDE HYDROCHLORIDE FOR INJECTION	*Constituted solution*	*USP37–NF32*	2290	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1: Change At the time of use, it meets the requirements for *Constituted Solutions* under *Labeling* under *Injections <1>*. to: At the time of use, it meets the requirements for *Constituted Solutions* under *Injections <1>*.
ERGOTAMINE TARTRATE	*Identification*	*USP37–NF32*	2826	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 4:Change value as the principal spot of *Standard solution A*. to: values as the corresponding spots of the *Standard preparation*.
LEVOTHYROXIM		*USP37–NF32*	3548	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First*	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NE SODIUM TABLETS	PUR ITIES/*Organic I mpurities/Proce dure: Limit of Liothyronine Sodium*						*Supplement to USP38–NF33*	*Acceptance criteria*: Change NMT 2.0% of liothyronine to: NMT 2.0% of liothyronine sodium
VITAMIN E	IDENTIFICATIO N/*A./Sample solutions*	*USP37–NF32*	5163	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Lines 4 and 7 of *Alpha tocopheryl acetate*: Change dilute sulfuric acid to: diluted sulfuric acid
CEFADROXIL CAPSULES	ADDITIONAL R EQUIREMENT S/*USP Reference Standards <11>*	*First Supplement to USP37–NF32*	6604	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 2 of USP Cefadroxil Related Compound I RS: Change (6*R*,7*R*)-7-[(*R*)-2-Amino-2-(4-hydroxyphenyl) acetamido]-3-m ethyl-8-oxo-5-thi a-1-azabicyclo[4.2.0]oct-2-ene-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								2-carboxylic acid monohydrate. to: (6*R*,7*R*)-7-[(*R*)-2-Amino-2-(4-hydroxyphenyl) acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid.
ALLOPURINOL	*USP Reference standards <11>*	*USP37–NF32*	1649	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 2 of USP Allopurinol Related Compound C RS: Change *N*-(4*H*-1,2,4-Triazol-4-yl)-1*H*-pyrazole-4-carboxamide. to: 5-(4*H*-1,2,4-Triazol-4-yl)-1*H*-pyrazole-4-carboxamide.
RISPERIDONE	ADDITIONAL R	*Second*	Online	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First*	Line 2 of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ORAL SOLUTION	EQUIREMENTS/*USP Reference Standards <11>*	*Supplement to USP37–NF32*					*Supplement to USP38–NF33*	Risperidone Related Compounds Mixture RS: Change Contains a mixture of the following four compounds: 98.9% of *Risperidone*. 0.5% of *Risperidone cis-N-oxide*: *cis*-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-*N*-oxide. 0.3% of *Bicyclorisperidone*: 3-(4-Fluoro-2-hydroxyphenyl)-1-[2-(6,7,8,9-t

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								etrahydro-2-methyl-4-oxo-4*H*-pyrido-[1,2-*a*]pyrimidin-3-yl)ethyl]-1-aza-2-azoniabicyclo[2.2.2]oct-2-ene iodide. 0.3% of *Z*-*Oxime*: (*Z*)-3-[2-[4-(2,4-Difluorophenyl)(hydroxyimino)methyl]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one. to: Contains a mixture of the following four compounds: Risperidone.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Risperidone *cis*-*N*-oxide: *cis* -3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, *N*-oxide. Bicyclorisperidone: 3-(4-Fluoro-2-hydroxyphenyl)-1-[2-(6,7,8,9-tetrahydro-2-methyl-4-oxo-4*H*-pyrido-[1,2-*a*]pyrimidin-3-yl)ethyl]-2-aza-1-azoniabicyclo[2.2.2]oct-2-ene iodide. *Z*-Oxime: (*Z*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-3-[2-[4-(2,4-Difluorophenyl)(hydroxyimino)methyl]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one.
CEFTRIAXONE INJECTION	*Assay*	*USP37–NF32*	2241	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Change *pH 7.0 Buffer*, *pH 5.0 Buffer*, *Mobile phase*, *Standard preparation*, *Resolution solution*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Ceftriaxone Sodium*. to: *pH 7.0 Buffer*—Dissolve 13.6 g of dibasic

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								potassium phosphate and 4.0 g of monobasic potassium phosphate in water to obtain 1000 mL of solution. Adjust this solution with phosphoric acid or 10 N potassium hydroxide to a pH of 7.0 ± 0.1. *pH 5.0 Buffer*—Dissolve 25.8 g of sodium citrate in 500 mL of water, adjust with citric acid solution (1 in 5) to a pH of 5.0 ± 0.1, and dilute with water to a volume of 1000 mL. *Mobile phase*—Dissolve 3.2 g of tetrahe

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ptylammonium bromide in 400 mL of acetonitrile, add 44 mL of *pH 7.0 Buffer* and 4 mL of *pH 5.0 Buffer*, and add water to make 1000 mL. Pass through a membrane filter of 0.5-?m or finer porosity, and degas. Make adjustments if necessary (see *System Suitability* under *Chromatography <621>*). *Standard preparation*—Dissolve an accurately weighed quantity of USP Ceftriaxone Sodium RS in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Mobile phase to obtain a solution having a known concentration of about 0.2 mg per mL. Use this solution promptly after preparation. *Resolution solution* —Dissolve a suitable quantity of USP Ceftriaxone Sodium *E* -Isomer RS in *Standard preparation*, and dilute with *Mobile phase* to obtain a solution containing about 160 µg of USP Ceftriaxone Sodium *E* -Isomer RSper mL and 160 µg

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								of USP Ceftriaxone Sodium RSper mL. Use this solution promptly after preparation. *Chromatographic system* (see *Chromatography <621>*)—The liquid chromatograph is equipped with a 270-nm detector and a 4.0-mm × 15-cm column that contains 5-?m packing L1. The flow rate is about 2 mL per minute. Chromatograph the *Resolution solution*, and record the peak responses as directed for *Procedure*. The resolution, *R*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								between the ceftriaxone *E* -isomer and ceftriaxone peaks is not less than 3. Chromatograph the *Standard preparation*, and record the peak responses as directed under *Procedure*. The column efficiency determined from the analyte peak is not less than 1500 theoretical plates, the tailing factor for the analyte is not more than 2, and the relative standard deviation for replicate injections is not

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								more than 2%. AND Change *Procedure*—Proceed as directed for *Procedure* in the *Assay* under *Ceftriaxone Sodium*. Calculate the quantity, in mg, of ceftriaxone ($C_{18}H_{18}N_8O_7S_3$) in each mL of the Injection taken by the formula: $200(C / V)(r_U / r_S)$ in which V is the volume, in mL, of Injection taken; and the other terms are as defined therein. to: *Procedure*—Separately

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								inject equal volumes (about 20 ?L) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of ceftriaxone ($C_{18}H_{18}N_8O_7S_3$) in each mL of Injection taken by the formula: $200(C / V)(r_U / r_S)$ in which C is the concentration, in mg per mL, of USP Ceftriaxone Sodium RS in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Standard preparation*; *V* is the volume, in mL, of Injection taken; and r_U and r_S are the ceftriaxone peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.
DOXEPIN HYDROCHLORIDE CAPSULES	PERFORMANCE TESTS	*USP37–NF32*	2712	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Change *Uniformity of Dosage Units, Content Uniformity <905>* to: *Uniformity of Dosage Units <905>*: Meet the requirements The following procedure is used where the test for *Content Uniformity* is

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								required. *Procedure for Content Uniformity* AND Delete a subsection: *Acceptance criteria:* Meet the requirements
LEVALBUTEROL HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP37–NF32*	3513	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 2 of USP Levalbuterol Related Compound H RS: Change 4-[2-(*tert*-Butylamino)-1-methoxyethyl]-2-(hydroxymethyl)phenol. $C_{14}H_{23}NO_3$ 253.34 to: 4-[2-(*tert*-Butylamino)-1-methoxyethyl]-2-(hydroxymethyl)phenol acetate. $C_{14}H_{23}NO_3 \cdot C$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$^{2}H_4O_2$ 313.39

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TICLOPIDINE HYDROCHLORIDE	IMPURITIES	*USP37–NF32*	4958	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Change *Residue on Ignition <231>* to: *Residue on Ignition <281>*
ATROPINE SULFATE	ASSAY/ *Procedure/System suitability/Suitability requirements*	*First Supplement to USP37–NF32*	6591	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1of *Relative standard deviation*: Change NMT 1.0 to: NMT 1.0%
PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS	DEFINITIONS	*USP37–NF32*	403	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Beyond-Use Date (BUD)*: Change The date after which a compounded preparation should not to be used; to: The date after which a compounded preparation shall not be used;

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TERBINAFINE HYDROCHLORIDE IMPURITIES		*First Supplement to USP37–NF32*	6704	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Footnotes b, c, and d of *Table 2*: Change [b]*trans*-Isoterbinafine or (*E*)-*N*,6,6-trimethyl-*N*-(naphthalen-2-ylmethyl)hept-2-en-4-yn-1-amine. [c]*cis*-Terbinafine or (*Z*)-*N*,6,6-trimethyl-*N*-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine. [d] 4-Methylterbinafine or (*E*)-*N*,6,6-trimethyl-*N*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-((4-methylnaphthalen-1-yl)methyl)hept-2-en-4-yn-1-amine. to: [b]*trans*-Isoterbinafine or (2*E*)-*N*, 6, 6-Trimethyl-*N*-(naphthalen-2-ylmethyl)hept-2-en-4-yn-1-amine. [c]*cis*-Terbinafine or (2*Z*)-*N*, 6, 6-Trimethyl-*N*-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine. [d] 4-Methylterbinafine or

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CEFAZOLIN INJECTION	*Assay*	*USP37–NF32*	2190	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	(2*E*)-*N*, 6, 6-Trimethyl-*N*-((4-methylnaphthalen-1-yl)methyl)hept-2-en-4-yn-1-amine. Change *pH 3.6 Buffer*, *pH 7.0 Buffer*, *Mobile phase*, *Internal standard solution*, *Standard preparation*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Cefazolin*. to: *pH 3.6 Buffer*—Dissolve 0.900 g of anhydrous dibasic sodium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								phosphate and 1.298 g of citric acid monohydrate in water to make 1000 mL. *pH 7.0 Buffer*—Dissolve 5.68 g of anhydrous dibasic sodium phosphate and 3.63 g of monobasic potassium phosphate in water to make 1000 mL. *Mobile phase*—Prepare a suitable mixture of *pH 3.6 Buffer* and acetonitrile (9:1). Pass through a membrane filter having a 10-?m or finer porosity, and degas. Make

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								adjustments if necessary (see *System Suitability* under *Chromatography <621>*). *Internal standard solution*—Transfer 750 mg of salicylic acid to a 100-mL volumetric flask, dissolve in 10 mL of methanol, dilute with *pH 7.0 Buffer* to volume, and mix. *Standard preparation*—Transfer about 25 mg of USP Cefazolin RS, accurately weighed, to a 25-mL volumetric flask, dissolve in and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dilute with *pH 7.0 Buffer* to volume, and mix. Transfer 5.0 mL of this solution to a 100-mL volumetric flask, add 5.0 mL of *Internal standard solution*, dilute with *pH 7.0 Buffer* to volume, and mix. *Chromatographic system* (see *Chromatography <621>*)—The liquid chromatograph is equipped with a 254-nm detector and a 4.0-mm × 30-cm column that contains 10-?m packing L1. The flow rate is about 2

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*. The relative retention times are about 0.7 for salicylic acid and 1.0 for cefazolin; the resolution, *R*, between the analyte and internal standard peaks is not less than 4.0; the column efficiency is not less than 1500 theoretical plates; the tailing factor is not more than 1.5; and the relative standard deviation for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								replicate injections is not more than 2.0%. AND Change *Proce dure*—Proceed as directed for *Procedure* in the *Assay* under *Cefazolin*. Calculate the quantity, in mg, of cefazolin ($C_{14}H_{14}N_8O_4S_3$) in each mL of the Injection taken by the formula: $(1000C / V)(R_U / R_S)$ in which V is the volume, in mL, of Injection taken, and the other terms are as defined therein. to: *Proce*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dure —Separately inject equal volumes (about 10 ?L) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of cefazolin ($C_{14}H_{14}N_8O_4S_3$) in each mL of Injection taken by the formula: $(1000C / V)(R_U / R_S)$ in which C is the concentration, in mg per mL, of USP Cefazolin

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS, calculated on the anhydrous basis, in the *Standard preparation*; *V* is the volume, in mL, of Injection taken; and R_U and R_S are the peak response ratios of cefazolin to the internal standard obtained from the *Assay preparation* and the *Standard preparation*, respectively.
CLOPIDOGREL BISULFATE	ASSAY/ *Procedure*	*USP37–NF32*	2422	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *System suitability solution*: Change 25 µg/mL of USP Clopidogrel Bisulfate RS and 50 µg/mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								USP Clopidogrel Related Compound B RS to: 2.5 µg/mL of USP Clopidogrel Bisulfate RS and 5.0 µg/mL of USP Clopidogrel Related Compound B RS
FLAVOXATE HYDROCHLORIDE	IMPURITIES	*USP37–NF32*	2988	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Row 3 of Column 1 of *Impurity Table 1*: Change Flavoxate related compound A[a,*] to: Flavoxate related compound A[a] AND Row 4 of Column 1 of *Impurity Table*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1: Change Flavoxate related compound B[b,*] to: Flavoxate related compound B[b] AND Row 5 of Column 1 of *Impurity Table 1*: Change Flavoxate related compound C[c,*] to: Flavoxate related compound C[c] AND Delete footnote *
MITOTANE TABLETS	*Assay*	*USP37–NF32*	3858	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Procedure*: Change Proceed as directed in the *Assay* under *Mitotane*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								beginning with “Concomitantly determine the absorbances of both solutions.” to: Concomitantly determine the absorbances of the *Assay preparation* and the *Standard preparation* in 1-cm cells at the wavelength of maximum absorbance at about 268 nm, with a suitable spectrophotometer, using methanol as the blank. Calculate the quantity, in mg, of $C_{14}H_{10}Cl_4$ in the portion of Tablets taken by the formula: $0.5C(A_U/A_S)$ in which *C* is

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the concentration, in mg/mL, of USP Mitotane RS in the *Standard preparation*, and A_U and A_S are the absorbances of the *Assay preparation* and the *Standard preparation*, respectively.
GELATIN	SPECIFIC TESTS/*Sulfur Dioxide/ Analysis*	*USP37–NF32*	5995	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 5 of the variable definition list: Change *m* = actual molarity of the *Titrant* (mol/mL) to: *m* = actual molarity of the *Titrant* (mol/L)
INSULIN ASPART	IDENTIFICATION/*B. Physicochemical Analytical Procedures for*	*First Supplement to USP37–NF32*	6647	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Column*: Change 4.0-mm × 25-cm; 5-µm

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Insulins, Peptide Mapping <121.1>/Chromatographic system							packing L7 to: 4.6-mm × 10-cm; 3-?m packing L1
AMIODARONE HYDROCHLORIDE	IM PURITIES/*Organic Impurities/Procedure 1*	*USP37–NF32*	1750	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 3 of *Acceptance criteria*: Change *Standard solution B* is not more intense to: the *Sample solution* is not more intense
QUINIDINE GLUCONATE EXTENDED-RELEASE TABLETS	ASSAY/*Procedure*	*USP37–NF32*	4515	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 2 of *System suitability solution*: Change dihydroquinidine chloride to: dihydroquinidine hydrochloride
DAPSONE TABLETS	IDENTIFICATION/*B. Ultraviolet Absorption <197U>*	*USP37–NF32*	2514	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Sample solution*: Delete Nominally 0.01 ?g/mL prepared

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								as follows.
SULFACETAMIDE SODIUM OPHTHALMIC OINTMENT	ASSAY/ *Procedure*	*USP37–NF32*	4765	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Sample solution*: Change USP Sulfacetamide Sodium RS to: sulfacetamide sodium
GADOPENTETATE DIMEGLUMINE INJECTION	IDENTIFICATION/*B.*	*USP37–NF32*	3113	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 2: Change 364.8 nm to: 368.4 nm
VALSARTAN	IMPURITIES	*USP37–NF32*	5115	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Footnote a of *Table 1*: Change (*S*)-*N*-Butyryl-*N*-([2?-(1*H*-tetrazole-5-yl)biphen-4-yl]methyl)-valine. to: *N*-Butyryl-*N*-{[2?-(1*H*-tetrazole-5-yl)bi

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								phenyl-4-yl]methyl}-L-valine. AND Footnote b of *Table 1*: Change (*S*)-*N* -Valeryl -*N* -([2?-(1*H* -tetrazole-5-yl)biphen-4-yl]methyl)-valine benzyl ester. to: *N* -Valeryl -*N* -{[2?-(1*H* -tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine benzyl ester.
STRONG IODINE SOLUTION	ASSAY	*USP37–NF32*	3354	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Acceptance criteria* in *Iodine*: Change of iodine (I) to: of iodine (I) in each 100 mL

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 1 of *Acceptance criteria* in *Potassium Iodide*: Change potassium iodide (KI) to: potassium iodide (KI) in each 100 mL

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 28
- Page 29
- Page 30
- Page 31
- Page 32
- Page 33
- Page 34
- Page 35
- Page 36
- …
- Next page Next ›
- Last page Last »